top of page
INSIGHTS
We equip our clients with actionable insights drawn from meticulous analysis of data, firsthand experience, and comprehensive interviews. The contextual evidence we provide enables quick, confident decision-making. We're known for our unique ability to view opportunities and challenges from both the company's and the customer's vantage points, offering a nuanced perspective that can't be found anywhere else.
Filter
From Big Firm to Own Boutique: Building value in Life Sciences Consulting
What does it take to build a consulting partnership that truly adapts to the realities of life sciences? In this episode of The Consulting Pulse, Spinnaker co-founder Dane Callow discusses how founder-led consulting, deep domain expertise, and senior-level engagement differentiate Spinnaker in a crowded market—helping life sciences companies navigate evolving operations, finance, and growth challenges.
Dane Callow
Dec 18, 20255 min read
The Einstellung Effect in Life Sciences Innovation: is Precedence Preventing Progress?
Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.
Daniel Yuan
Dec 8, 20255 min read
When Delivery Becomes Life Cycle Management Strategy in Biopharma: Merck’s Subcutaneous Keytruda
Merck’s subcutaneous (SC) Keytruda, FDA-approved on Sept 19, 2025, transforms cancer care delivery by replacing 30-minute infusions with 1–2 minute injections. This shift frees oncology clinic capacity, enhances patient access, and redefines value creation in immuno-oncology. By integrating delivery efficiency into strategy, Merck positions Keytruda’s SC formulation as a competitive and operational milestone in oncology’s evolving landscape.
Fraol Galan
Oct 22, 20257 min read
Phase 3 Isn’t Just a Regulatory Milestone: It’s the Start of Product Differentiation
Phase 3 isn’t just a regulatory milestone—it’s a product’s pseudo launch. In today’s competitive biopharma landscape, success depends on building product differentiation early, not after approval. The design of late-stage trials shapes labeling, messaging, and market access. By embedding differentiation into clinical strategy, companies can turn regulatory readiness into true commercial advantage.
Spinnaker Staff
Jul 17, 20253 min read
Why Pharma’s CNS Bet Is Moving to Psychiatry
Psychiatry is emerging as the most capital-efficient segment in CNS, attracting major biopharma investment with late-phase assets, validated endpoints, and scalable commercial models. As neurodegeneration remains high-risk, psychiatry offers near-term ROI and strategic fit across the value chain.
Fraol Galan
Jul 8, 20255 min read
Expanding GLP-1s: is Neurology the Next Frontier?
GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.
Federico Somaini
Apr 2, 20255 min read
bottom of page